Literature DB >> 26548921

Distinct encounter complexes of PAI-1 with plasminogen activators and vitronectin revealed by changes in the conformation and dynamics of the reactive center loop.

Tihami Qureshi1, Sumit Goswami1, Carlee S McClintock1, Matthew T Ramsey1, Cynthia B Peterson1.   

Abstract

UNLABELLED: Plasminogen activator inhibitor-1 (PAI-1) is a biologically important serine protease inhibitor (serpin) that, when overexpressed, is associated with a high risk for cardiovascular disease and cancer metastasis. Several of its ligands, including vitronectin, tissue-type and urokinase-type plasminogen activator (tPA, uPA), affect the fate of PAI-1. Here, we measured changes in the solvent accessibility and dynamics of an important unresolved functional region, the reactive center loop (RCL), upon binding of these ligands. Binding of the catalytically inactive S195A variant of tPA to the RCL causes an increase in fluorescence, indicating greater solvent protection, at its C-terminus, while mobility along the loop remains relatively unchanged. In contrast, a fluorescence increase and large decrease in mobility at the N-terminal RCL is observed upon binding of S195A-uPA to PAI-1. At a site distant from the RCL, binding of vitronectin results in a modest decrease in fluorescence at its proximal end without restricting overall loop dynamics. These results provide the new evidence for ligand effects on RCL conformation and dynamics and differences in the Michaelis complex with plasminogen activators that can be used for the development of more specific inhibitors to PAI-1. This study is also the first to use electron paramagnetic resonance (EPR) spectroscopy to investigate PAI-1 dynamics. SIGNIFICANCE: Balanced blood homeostasis and controlled cell migration requires coordination between serine proteases, serpins, and cofactors. These ligands form noncovalent complexes, which influence the outcome of protease inhibition and associated physiological processes. This study reveals differences in binding via changes in solvent accessibility and dynamics within these complexes that can be exploited to develop more specific drugs in the treatment of diseases associated with unbalanced serpin activity.
© 2015 The Protein Society.

Entities:  

Keywords:  electron paramagnetic resonance (EPR); fluorescence; plasminogen activator inhibitor-1 (PAI-1); reactive center loop (RCL); serpin; tissue plasminogen activator (tPA); urokinase plasminogen activator (uPA); vitronectin

Mesh:

Substances:

Year:  2015        PMID: 26548921      PMCID: PMC4815334          DOI: 10.1002/pro.2841

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  64 in total

Review 1.  A new spin on protein dynamics.

Authors:  Linda Columbus; Wayne L Hubbell
Journal:  Trends Biochem Sci       Date:  2002-06       Impact factor: 13.807

Review 2.  The contribution of L-arginine to the neurotoxicity of recombinant tissue plasminogen activator following cerebral ischemia: a review of rtPA neurotoxicity.

Authors:  George W J Harston; Brad A Sutherland; James Kennedy; Alastair M Buchan
Journal:  J Cereb Blood Flow Metab       Date:  2010-08-25       Impact factor: 6.200

3.  Metals affect the structure and activity of human plasminogen activator inhibitor-1. I. Modulation of stability and protease inhibition.

Authors:  Lawrence C Thompson; Sumit Goswami; David S Ginsberg; Duane E Day; Ingrid M Verhamme; Cynthia B Peterson
Journal:  Protein Sci       Date:  2011-02       Impact factor: 6.725

4.  Systemic fibrinolysis caused by tissue plasminogen activator-producing metastatic breast cancer.

Authors:  Harris V K Naina; Mrinal M Patnaik; Uzma A Ali; Dong Chen; Aneel A Ashrani
Journal:  J Clin Oncol       Date:  2010-01-11       Impact factor: 44.544

5.  The use of fluorescent probes to characterize conformational changes in the interaction between vitronectin and plasminogen activator inhibitor-1.

Authors:  A Gibson; K Baburaj; D E Day; I Verhamme; J D Shore; C B Peterson
Journal:  J Biol Chem       Date:  1997-02-21       Impact factor: 5.157

6.  Serpin latency transition at atomic resolution.

Authors:  Giorgia Cazzolli; Fang Wang; Silvio a Beccara; Anne Gershenson; Pietro Faccioli; Patrick L Wintrode
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-13       Impact factor: 11.205

7.  Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients.

Authors:  Qingyong Chen; Jun Fei; Lijun Wu; Zhongyong Jiang; Yuquan Wu; Yun Zheng; Guohua Lu
Journal:  Oncol Lett       Date:  2011-05-11       Impact factor: 2.967

Review 8.  Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies.

Authors:  Rao Muralikrishna Adibhatla; James F Hatcher
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-06       Impact factor: 4.388

9.  Introduction to spin label electron paramagnetic resonance spectroscopy of proteins.

Authors:  Michelle Melanson; Abha Sood; Fanni Török; Marianna Török
Journal:  Biochem Mol Biol Educ       Date:  2012-12-27       Impact factor: 1.160

Review 10.  The 'PAI-1 paradox' in vascular remodeling.

Authors:  Isabel Diebold; Damir Kraicun; Steve Bonello; Agnes Görlach
Journal:  Thromb Haemost       Date:  2008-12       Impact factor: 5.249

View more
  3 in total

1.  Molecular mechanism of two nanobodies that inhibit PAI-1 activity reveals a modulation at distinct stages of the PAI-1/plasminogen activator interaction.

Authors:  Machteld Sillen; Stephen D Weeks; Xiaohua Zhou; Andrey A Komissarov; Galina Florova; Steven Idell; Sergei V Strelkov; Paul J Declerck
Journal:  J Thromb Haemost       Date:  2020-02-20       Impact factor: 5.824

2.  Reactive centre loop dynamics and serpin specificity.

Authors:  Emilia M Marijanovic; James Fodor; Blake T Riley; Benjamin T Porebski; Mauricio G S Costa; Itamar Kass; David E Hoke; Sheena McGowan; Ashley M Buckle
Journal:  Sci Rep       Date:  2019-03-07       Impact factor: 4.379

Review 3.  Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition.

Authors:  Machteld Sillen; Paul J Declerck
Journal:  Front Cardiovasc Med       Date:  2020-12-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.